01/19/2022
https://twitter.com/asco/status/1482412271225741316?s=21
“Many studies investigating targeting w trastuzumab combo therapy, such as HERACLES-A, MOUNTAINEER, & DESTINY-CRC01, have had encouraging results & demonstrate the potential of these therapies for patients w . https://t.co/e2NZoyOEgp ”